Clinical trials
Rare Diseases trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
40 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2007 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 6 |
| 2020 | 2 |
| 2021 | 5 |
| 2022 | 3 |
| 2023 | 6 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 14 |
| Unknown status | 11 |
| Completed | 9 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
| Terminated | 1 |
| Enrolling by invitation | 1 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital Tuebingen | 11 |
| Wuerzburg University Hospital | 4 |
| Friedreich's Ataxia Research Alliance | 2 |
| Novartis Pharmaceuticals | 2 |
| RWTH Aachen University | 2 |
| University of Bonn | 2 |
| Universitätsklinikum Hamburg-Eppendorf | 2 |
| Aspa Therapeutics | 1 |
| AstraZeneca | 1 |
| Imagine Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Rare Diseases | 40 |
| Genetic Predisposition to Disease | 8 |
| Neurodegenerative Diseases | 4 |
| Fabry Disease | 3 |
| Friedreich Ataxia | 3 |
| Genetic Diseases, Inborn | 3 |
| Bone Diseases, Metabolic | 2 |
| Cardiomyopathy, Hypertrophic | 2 |
| Genetic Risk Score | 2 |
| Huntington Disease | 2 |
Trials
Showing 1 to 25 of 40. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.